Table 2.
Prevalence of resistance to Rifampicin and MDR-TB in smear-positive patients with pulmonary TB, Djibouti nationwide drug-resistance survey, 2014–2015.
| New cases (n = 301) | Previously treated cases (n = 66) | Total (n = 367) | ||||
|---|---|---|---|---|---|---|
| n | % (95%CI) | n | % (95%CI) | n | % (95%CI) | |
| Rifampicin-resistance | 14 | 4.7% (2.8; 7.7) | 23* | 34.9% (24.5; 46. 9) | 37 | 10.1% (7.4; 13.6) |
| MDR-TB | 14 | 4.7% (2.8; 7.7) | 20 | 30.8% (20. 9; 42.8) | 34 | 9.3% (7.2; 14.6) |
*Isoniazid susceptibility testing was available for 22 out of 23 rifampicin resistant previously treated TB patients.